Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

1.

Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy.

Tietze JK, Wilkins DE, Sckisel GD, Bouchlaka MN, Alderson KL, Weiss JM, Ames E, Bruhn KW, Craft N, Wiltrout RH, Longo DL, Lanier LL, Blazar BR, Redelman D, Murphy WJ.

Blood. 2012 Mar 29;119(13):3073-83. doi: 10.1182/blood-2011-07-369736. Epub 2012 Jan 17.

2.

Influenza infection results in local expansion of memory CD8(+) T cells with antigen non-specific phenotype and function.

Sckisel GD, Tietze JK, Zamora AE, Hsiao HH, Priest SO, Wilkins DE, Lanier LL, Blazar BR, Baumgarth N, Murphy WJ.

Clin Exp Immunol. 2014 Jan;175(1):79-91. doi: 10.1111/cei.12186.

3.

Bystander activation and anti-tumor effects of CD8+ T cells following Interleukin-2 based immunotherapy is independent of CD4+ T cell help.

Monjazeb AM, Tietze JK, Grossenbacher SK, Hsiao HH, Zamora AE, Mirsoian A, Koehn B, Blazar BR, Weiss JM, Wiltrout RH, Sckisel GD, Murphy WJ.

PLoS One. 2014 Aug 13;9(8):e102709. doi: 10.1371/journal.pone.0102709. eCollection 2014.

4.

Intracellular bacterial vectors that induce CD8(+) T cells with similar cytolytic abilities but disparate memory phenotypes provide contrasting tumor protection.

Stark FC, Sad S, Krishnan L.

Cancer Res. 2009 May 15;69(10):4327-34. doi: 10.1158/0008-5472.CAN-08-3160. Epub 2009 May 12.

5.

IL-21 and IL-15 cytokine DNA augments HSV specific effector and memory CD8+ T cell response.

Rodrigues L, Nandakumar S, Bonorino C, Rouse BT, Kumaraguru U.

Mol Immunol. 2009 Apr;46(7):1494-504. doi: 10.1016/j.molimm.2008.12.033. Epub 2009 Feb 23.

PMID:
19233474
6.

Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.

Wu F, Zhang W, Shao H, Bo H, Shen H, Li J, Liu Y, Wang T, Ma W, Huang S.

Cancer Lett. 2013 Oct 10;339(2):195-207. doi: 10.1016/j.canlet.2013.06.009. Epub 2013 Jun 18.

PMID:
23791878
7.

Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors.

Teague RM, Sather BD, Sacks JA, Huang MZ, Dossett ML, Morimoto J, Tan X, Sutton SE, Cooke MP, Ohlén C, Greenberg PD.

Nat Med. 2006 Mar;12(3):335-41. Epub 2006 Feb 12.

PMID:
16474399
9.

Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction.

André MC, Sigurdardottir D, Kuttruff S, Pömmerl B, Handgretinger R, Rammensee HG, Steinle A.

Int J Cancer. 2012 Oct 1;131(7):1601-10. doi: 10.1002/ijc.26191. Epub 2011 Aug 1.

10.

Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.

Contreras A, Sen S, Tatar AJ, Mahvi DA, Meyers JV, Srinand P, Suresh M, Cho CS.

Cancer Immunol Immunother. 2016 May;65(5):601-11. doi: 10.1007/s00262-016-1823-8. Epub 2016 Mar 24.

11.

Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.

Rolle CE, Carrio R, Malek TR.

Cancer Res. 2008 Apr 15;68(8):2984-92. doi: 10.1158/0008-5472.CAN-07-3040.

12.

Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy.

Snook AE, Magee MS, Schulz S, Waldman SA.

Eur J Immunol. 2014 Jul;44(7):1956-66. doi: 10.1002/eji.201444539. Epub 2014 May 21.

14.

T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing.

Zhou Q, Schneider IC, Edes I, Honegger A, Bach P, Schönfeld K, Schambach A, Wels WS, Kneissl S, Uckert W, Buchholz CJ.

Blood. 2012 Nov 22;120(22):4334-42. doi: 10.1182/blood-2012-02-412973. Epub 2012 Aug 16.

15.

In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.

Tomala J, Chmelova H, Mrkvan T, Rihova B, Kovar M.

J Immunol. 2009 Oct 15;183(8):4904-12. doi: 10.4049/jimmunol.0900284.

16.

IL-15-dependent induction of 4-1BB promotes antigen-independent CD8 memory T cell survival.

Pulle G, Vidric M, Watts TH.

J Immunol. 2006 Mar 1;176(5):2739-48.

17.

IL-27 enhances the survival of tumor antigen-specific CD8+ T cells and programs them into IL-10-producing, memory precursor-like effector cells.

Liu Z, Liu JQ, Talebian F, Wu LC, Li S, Bai XF.

Eur J Immunol. 2013 Feb;43(2):468-79. doi: 10.1002/eji.201242930. Epub 2013 Jan 15.

18.

Differential responsiveness to IL-2, IL-7, and IL-15 common receptor gamma chain cytokines by antigen-specific peripheral blood naive or memory cytotoxic CD8+ T cells from healthy donors and melanoma patients.

Rosenthal R, Groeper C, Bracci L, Adamina M, Feder-Mengus C, Zajac P, Iezzi G, Bolli M, Weber WP, Frey DM, von Holzen U, Oertli D, Heberer M, Spagnoli GC.

J Immunother. 2009 Apr;32(3):252-61. doi: 10.1097/CJI.0b013e3181998e03.

PMID:
19242375
19.

CD8+ T-cell memory in tumor immunology and immunotherapy.

Klebanoff CA, Gattinoni L, Restifo NP.

Immunol Rev. 2006 Jun;211:214-24. Review.

20.

Increased memory conversion of naïve CD8 T cells activated during late phases of acute virus infection due to decreased cumulative antigen exposure.

Fousteri G, Dave A, Juedes A, Juntti T, Morin B, Togher L, Farber DL, von Herrath M.

PLoS One. 2011 Jan 6;6(1):e14502. doi: 10.1371/journal.pone.0014502.

Supplemental Content

Support Center